Search
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
go.drugbank.com/drugs/DB13948ExperimentalIt has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.
Synonyms: NBOH-2C-CN, N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineRepotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigationalThis approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741] … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the
Morus alba pollen
go.drugbank.com/drugs/DB10480ApprovedMorus alba pollen is mainly used in allergenic testing.
Mixtures: Treatment Set TS333938, Treatment Set TS128872Quinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnIt is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand name Norprolac contained as a racemate. … Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States.
Synonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideProducts: Norprolac 0,025 mg u. 0,050 mg - Tabletten (Startpackung), NORPROLAC® 0.025 MGDitiocarb zinc
go.drugbank.com/drugs/DB14193ApprovedIt also a dermatological sensitizer and allergen. Sensitivity to ditiocarb zinc may be identified with a clinical patch test.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Zinc N,N-diethyldithiocarbamateQuinethazone
go.drugbank.com/drugs/DB01325ApprovedQuinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigational[L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508] … After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024.
OPC-28326
go.drugbank.com/drugs/DB05461ExperimentalIt is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary
Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10779ApprovedInvestigationalThis defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it
Mixtures: Fluarix Tetra Injektionssuspension in einer FertigspritzeDifamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigationalThe drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States. … [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production